These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15761604)

  • 41. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study.
    Zanetti AR; Romanò L; Giambi C; Pavan A; Carnelli V; Baitelli G; Malchiodi G; Valerio E; Barale A; Marchisio MA; Montù D; Tozzi AE; D'Ancona F;
    Lancet Infect Dis; 2010 Nov; 10(11):755-61. PubMed ID: 20884297
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Comparison of two different vaccination schemes against Hepatitis A and B in Mexican children and adolescents].
    González-Huezo MS; Sánchez-Avila F; García Mayol M; Castro Narro G; Sixtos S; Lisker-Melman M; Kershenobich D
    Rev Gastroenterol Mex; 2003; 68(4):271-6. PubMed ID: 15125329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents.
    Schiff GM; Sherwood JR; Zeldis JB; Krause DS
    J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
    Samandari T; Fiore AE; Negus S; Williams JL; Kuhnert W; McMahon BJ; Bell BP
    Pediatrics; 2007 Aug; 120(2):e373-81. PubMed ID: 17636112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity, reactogenicity and safety of two-dose versus three-dose (standard care) hepatitis B immunisation of healthy adolescents aged 11-15 years: a randomised controlled trial.
    Heron L; Selnikova O; Moiseieva A; Van Damme P; van der Wielen M; Levie K; Hoet B; Stoffel M
    Vaccine; 2007 Apr; 25(15):2817-22. PubMed ID: 17276552
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
    Vesikari T; Langley JM; Segall N; Ward BJ; Cooper C; Poliquin G; Smith B; Gantt S; McElhaney JE; Dionne M; van Damme P; Leroux-Roels I; Leroux-Roels G; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson DE; Popovic V; Diaz-Mitoma F;
    Lancet Infect Dis; 2021 Sep; 21(9):1271-1281. PubMed ID: 33989539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunization against hepatitis B in children from endemic zone: evaluation of the antibody response against the DNA recombinant vaccine (Engerix B-20 MCG).
    Ferreira CR; Yoshida CF; Mercadante LA; Gomes DF; Oliveira JM; França MS; Sidoni M; Ennes IC; Baptista ML; Schatzmayr HG
    Rev Inst Med Trop Sao Paulo; 1993; 35(1):89-92. PubMed ID: 8278748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
    Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
    Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transient surface antigenemia in newborn infants vaccinated with Engerix B: occurrence and duration.
    Weintraub Z; Khamaysi N; Elena H; Gershtein V; Orenstein L; Lahat N
    Pediatr Infect Dis J; 1994 Oct; 13(10):931-3. PubMed ID: 7854896
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates.
    Bassily S; Kotkat A; Gray G; Hyams KC; Brown FM; Imam IZ; Arthur R
    Am J Trop Med Hyg; 1995 Oct; 53(4):419-22. PubMed ID: 7485697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of two recombinant hepatitis B vaccines and their interchangeability in Argentine infants.
    Tregnaghi M; Ussher J; Baudagna AM; Calvari M; Graña G
    Rev Panam Salud Publica; 2004 Jan; 15(1):35-40. PubMed ID: 14987456
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison of immunogenicity and safety of Engerix B and Twinrix vaccine].
    Gałaj A; Grześk G; Borys D; Durmowicz A; Grześk E; Szadujkis-Szadurski L
    Wiad Lek; 2004; 57(5-6):217-20. PubMed ID: 15518064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults.
    Joines RW; Blatter M; Abraham B; Xie F; De Clercq N; Baine Y; Reisinger KS; Kuhnen A; Parenti DL
    Vaccine; 2001 Sep; 19(32):4710-9. PubMed ID: 11535321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of immunogenicity and reactogenicity of recombinant DNA hepatitis B vaccine produced in India.
    Hussain Z; Ali SS; Husain SA; Raish M; Sharma DR; Kar P
    World J Gastroenterol; 2005 Dec; 11(45):7165-8. PubMed ID: 16437665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine.
    Shapira MY; Zeira E; Adler R; Shouval D
    J Hepatol; 2001 Jan; 34(1):123-7. PubMed ID: 11211888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers.
    Thaithumyanon P; Punnahitananda S; Praisuwanna P; Thisyakorn U; Ruxrungtham K
    J Med Assoc Thai; 2002 Mar; 85(3):277-82. PubMed ID: 12117014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy neonates.
    Minervini G; McCarson BJ; Reisinger KS; Martin JC; Stek JE; Atkins BM; Nadig KB; Liska V; Schödel FP; Bhuyan PK
    Vaccine; 2012 Feb; 30(8):1476-80. PubMed ID: 22227229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
    Cooper CL; Davis HL; Angel JB; Morris ML; Elfer SM; Seguin I; Krieg AM; Cameron DW
    AIDS; 2005 Sep; 19(14):1473-9. PubMed ID: 16135900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates.
    Goldfarb J; Baley J; Medendorp SV; Seto D; Garcia H; Toy P; Watson B; Gooch MW; Krause D
    Pediatr Infect Dis J; 1994 Jan; 13(1):18-22. PubMed ID: 8170727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.